Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to take steps with the Secretary of State for Defence to create a formal framework for supporting NHS-employed clinicians who serve as medical Reservists.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Clinicians who serve as Reservists play a vital role in supporting both the National Health Service and the Armed Forces. The Department of Health and Social Care and the Ministry of Defence work with NHS Employers to ensure that NHS organisations are supportive and flexible when it comes to people joining the Armed Forces Reserve, and to enable individuals to train and deploy when needed. All NHS trusts are signed up to the Armed Forces Covenant and all have been awarded an Employer Recognition Scheme award to reflect their commitment to supporting our Armed Forces, including the Reserves.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of NHS staffing shortages on the availability of medical Reservists for the armed forces.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
No specific assessment has been made. NHS Employers, which is part of the NHS Confederation and supports workforce development across the National Health Service, runs a programme that is funded by the Department of Health and Social Care and the Ministry of Defence to encourage NHS organisations to be supportive and flexible employers when it comes to people joining the Armed Forces Reserve. This ensures that people with the critically important skills that the reserves are looking for, such as doctors, are able to train and deploy when needed.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has considered a Sponsored Reserve model or similar arrangement to enable NHS clinicians to contribute directly to Defence Medical Services while maintaining NHS employment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There have been no formal considerations for the implementation of a Sponsored Reserve model within the National Health Service. The Department of Health and Social Care, in partnership with the Ministry of Defence, is focused on growing and maintaining the Active Armed Forces reserve and works with NHS organisations to enable individuals to train and deploy when needed.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of increases in National Insurance contributions on the financial sustainability of charitable hospices and the delivery of end-of-life care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We took the necessary decisions to fix the foundations in the public finances at the Autumn Budget, enabling the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The employer National Insurance contribution rise was implemented in April 2025, and planning guidance published on 30 January 2025 sets out the funding available to integrated care boards and the overall approach to funding providers for the 2025/26 financial year. It takes into account a variety of pay and non-pay factors and pressures on providers of secondary healthcare, including charitable hospices. Further information on the planning guidance is available at the following link:
https://www.england.nhs.uk/publication/2025-26-priorities-and-operational-planning-guidance/
We are supporting the hospice sector with a £100 million capital funding boost for adult and children’s hospices in England, to ensure they have the best physical environment for care. I am delighted that the first £25 million tranche of that funding, which Hospice UK kindly allocated and distributed to hospices throughout England, was fully spent by hospices on capital projects. An additional £75 million will be allocated in the coming weeks for use in 2025/26.
We are also providing £26 million of revenue funding to support children and young people’s hospices for 2025/26. This is a continuation of the funding which until recently was known as the children and young people’s hospice grant.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of changes to hospice funding on the sustainability of end-of-life care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.
Whilst the majority of palliative and end of life care is provided by National Health Service staff and services, we recognise the vital part that voluntary sector organisations, including hospices, also play in providing support to people at end of life and their loved ones.
In recognition of this, we are supporting the hospice sector with a £100 million capital funding boost for adult and children’s hospices in England for 2024/25 and 2025/26, to ensure they have the best physical environment for care.
Additionally, children and young people’s hospices will receive £26 million in revenue funding for 2025/26. This is a continuation of the funding which until recently was known as the children and young people’s hospice grant.
In February, I met with key palliative care and end of life care and hospice stakeholders, in a roundtable format, with a focus on long-term sector sustainability within the context of our 10-Year Health Plan.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled New services for patients under record pharmacy funding deal, published on 31 March 2025, what proportion of the additional funding for community pharmacies was allocated to meet the cost of increases to (a) employer National Insurance Contributions (b) business rates and (c) National Minimum Wage in (i) 2024/25 and (ii) 2025/26.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have taken the necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The Department has considered the increases in the National Living Wage and employer national insurance when consulting on the funding arrangements for community pharmacy. We have now agreed with Community Pharmacy England to increase the community pharmacy contractual framework to £3.073 billion from April 2025. This deal represents the largest uplift in funding of any part of the National Health Service, at over 19% across 2024/25 and 2025/26.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the cost to community pharmacies of changes in the level of (a) employer National Insurance contributions, (b) business rates and (c) the National Minimum Wage from 1 April 2025.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have taken the necessary decisions to fix the foundations in the public finances at the Autumn Budget, which enabled the Spending Review settlement of a £22.6 billion increase in resource spending for the Department from 2023/24 outturn to 2025/26.
The Department has considered the increases in the National Living Wage and employer national insurance when consulting on the funding arrangements for community pharmacy. We have now agreed with Community Pharmacy England to increase the community pharmacy contractual framework to £3.073 billion from April 2025. This deal represents the largest uplift in funding of any part of the National Health Service, at over 19% across 2024/25 and 2025/26.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the (a) development and (b) approval of (i) second- and third-line tyrosine kinase inhibitors and (ii) other targeted therapy options for patients with ROS1-positive cancer; and whether his Department has had recent discussions with (A) the National Institute for Health and Care Excellence and (B) pharmaceutical companies on encouraging clinical trial funding in this area.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. The NICE evaluates all new licensed cancer medicines and aims wherever possible to issue recommendations close to the time of licensing. The NHS in England is legally required to fund treatments recommended by the NICE. The NICE published guidance that recommends the tyrosine kinase inhibitors crizotinib and entrectinib for use in the treatment of people with ROS1 positive advanced non-small cell lung cancer who have not previously been treated with ROS1 inhibitors. These treatments are now routinely funded by the NHS for eligible patients.
The Department has had no discussions with the NICE or pharmaceutical companies on encouraging clinical trial funding in this area. The Department is working closely with the NHS, industry, academia, research regulators, and charities to make clinical research in the United Kingdom more efficient, more competitive, and more accessible. We expect these efforts to attract more commercial investment in clinical research and yield a broad and diverse portfolio of clinical trials in the UK, including clinical trials for cancer. The Department funded National Institute for Health and Care Research (NIHR) funds research and research infrastructure, which supports patients and the public to participate in high-quality research, including clinical research on cancer. NIHR research expenditure for all cancers was £133 million in 2023/24, reflecting its high priority. These investments are pivotal towards efforts to improve cancer prevention, treatment, and outcomes.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 31 March 2025 to Question 40741 on Health Services: Public Consultation, what was the cost to the public purse of (a) travel and (b) accommodation for the 11 working groups supporting the development of the 10-Year Health Plan.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has met the costs of travel and accommodation for a small number of working group members. The total cost to date is £912.25, which is made up of £750.35 of travel expenses, and £162.00 for accommodation.
Asked by: Neil Shastri-Hurst (Conservative - Solihull West and Shirley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled New services for patients under record pharmacy funding deal, published on 31 March 2025, what types of mental health support will community pharmacies offer to patients.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The New Medicine Service (NMS) is an advanced service offered by community pharmacies, providing patients with advice to address any possible side effects, issues, or questions that patients who are prescribed a new medicine may have. The service focuses on treatments for long-term conditions, including asthma and hypertension.
Early interventions of this type can improve medication adherence, patient outcomes, and can reduce pressure on the wider National Health Service. From October 2025, the NMS will expand to introduce depression as a further therapeutic area for which patients can receive support.